The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

I have always believed that if you have an appointment with an eye doctor, you should show up late. When the doctor asks why ...

The most common adverse reactions reported with Susvimo were conjunctival hemorrhage, conjunctival hyperemia, iritis, eye pain, cataract, conjunctival disorder, and vitreous hemorrhage.

A new study from the Koret School of Veterinary Medicine at Hebrew University has brought new insights into Florida spot ...

The most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure, while the most common nonocular side effects included ...

The most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters and increased intraocular pressure, while the most common nonocular side effects included ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...